Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 million

PUBT · 1d ago
Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 million
  • Immix Biopharma posted a net loss of USD 11.56 million for the quarter ended June 30, 2026, widening from USD 6.62 million a year earlier.
  • General and administrative expense climbed to USD 7.12 million from USD 2.75 million, driven by higher compensation and professional fees tied to capital-raising.
  • Research and development expense rose to USD 5.33 million from USD 3.97 million, on higher clinical-trial and licensing costs; USD 0.5 million of CIRM reimbursements offset R&D.
  • Interest income increased to USD 913,663 from USD 104,056 as the company maintained higher balances in money market funds and US Treasuries.
  • Enrollment in the Phase 1b/2 NEXICART-2 trial of CAR-T NXC-201 is complete with 45 patients; the company plans a randomized Phase 3 study in newly diagnosed AL amyloidosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036643), on August 07, 2026, and is solely responsible for the information contained therein.